Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJian LiMDMark R. DowlingVVVinay Vanguru

Discussion

Loading...

Member takes

Overview

Real-world findings show CAR T-cell therapy improves progression-free survival in patients with Richter transformation, suggesting promising treatment potential.

Key Points

  • Assess the outcomes of CAR T-cell therapy in patients with Richter transformation of chronic lymphocytic leukemia.
  • Multi-centre cohort study with 28 patients receiving CAR T-cell therapy.
  • Patients had histologically confirmed diffuse large B-cell lymphoma related to chronic lymphocytic leukemia.
  • Primary endpoints: 12-month progression-free survival and overall response rate post-infusion.
  • One-month overall response rate was 75%, including 54% complete responses.
  • 12-month progression-free survival rate was estimated at 47%, with overall survival at 61%.
  • Severe cytokine release syndrome and neurotoxicity were uncommon (both 8%).

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da56https://doi.org/10.1182/blood-2025-2779
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study2024 · 46 citations
  2. 2Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization2025 · 2 citations
  3. 3Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience2025
  4. 4Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation2025
  5. 5A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium2025 · 2 citations